The endothelial layer is a barrier through which circulating oncolytic viruses and virus-infected cell carriers must cross to access tumor cells. We propose that addition of vascular binding motifs on the surfaces of oncolytic measles viruses (or virus-infected cell carriers) allows them to recognize and bind to unique antigenic markers on the lumenal surface of endothelial cells that line the tumor neovasculature, thereby enhancing their localization/arrest at the tumor site. Using the versatile measles virus display platform, we have generated dual tropic measles viruses (vascular binding and tumor tropic) and demonstrated that after intravascular administration, measles viruses displaying a??3 integrin binding motifs, but not parental virus, can interact with the lumenal surface of endothelial cells in the neovessels. The bound viruses can extravasate through fenestrations between endothelial cells, transcytose through or infect the endothelial cell to cross the endothelial barrier and infect underlying tumor cells. We are now poised to test the hypotheses that 1) chimeric MV with added vascular binding motifs (and cell carriers infected with these viruses) will have enhanced localization at sites of tumor growth and 2) such dual tropic vascular binding MV (and virus-infected cell carriers) will have enhanced anti-tumor efficacy compared to parental viruses that cannot interact with tumor neovessels.

Public Health Relevance

Systemically administered therapeutic viruses and virus loaded cell carriers do not always arrive at the tumor site. This grant seeks to improve the tumor localization of measles viruses and virus infected cell carriers by adding vascular binding motifs on their surfaces to enhance their attachment/arrest at tumor neovessels and tumor sites.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
5R01CA129193-05
Application #
8403539
Study Section
Gene and Drug Delivery Systems Study Section (GDD)
Program Officer
Yovandich, Jason L
Project Start
2009-02-01
Project End
2014-12-31
Budget Start
2013-01-01
Budget End
2013-12-31
Support Year
5
Fiscal Year
2013
Total Cost
$344,282
Indirect Cost
$125,968
Name
Mayo Clinic, Rochester
Department
Type
DUNS #
006471700
City
Rochester
State
MN
Country
United States
Zip Code
55905
Ayala-Breton, Camilo; Russell, Luke O J; Russell, Stephen J et al. (2014) Faster replication and higher expression levels of viral glycoproteins give the vesicular stomatitis virus/measles virus hybrid VSV-FH a growth advantage over measles virus. J Virol 88:8332-9
Liu, Yu-Ping; Steele, Michael B; Suksanpaisan, Lukkana et al. (2014) Oncolytic measles and vesicular stomatitis virotherapy for endometrial cancer. Gynecol Oncol 132:194-202
Suksanpaisan, L; Russell, S J; Peng, K-W (2014) High scFv-receptor affinity does not enhance the antitumor activity of HER2-retargeted measles virus. Cancer Gene Ther 21:256-60
Liu, Yu-Ping; Russell, Samuel P; Ayala-Breton, Camilo et al. (2014) Ablation of nectin4 binding compromises CD46 usage by a hybrid vesicular stomatitis virus/measles virus. J Virol 88:2195-204
Liu, Yu-Ping; Wang, Jiahu; Avanzato, Victoria A et al. (2014) Oncolytic vaccinia virotherapy for endometrial cancer. Gynecol Oncol 132:722-9
Mader, Emily K; Butler, Greg; Dowdy, Sean C et al. (2013) Optimizing patient derived mesenchymal stem cells as virus carriers for a phase I clinical trial in ovarian cancer. J Transl Med 11:20
Suksanpaisan, L; Pham, L; McIvor, S et al. (2013) Oral contrast enhances the resolution of in-life NIS reporter gene imaging. Cancer Gene Ther 20:638-41
Ayala-Breton, Camilo; Suksanpaisan, Lukkana; Mader, Emily K et al. (2013) Amalgamating oncolytic viruses to enhance their safety, consolidate their killing mechanisms, and accelerate their spread. Mol Ther 21:1930-7
Liu, Chunsheng; Suksanpaisan, Lukkana; Chen, Yun-Wen et al. (2013) Enhancing cytokine-induced killer cell therapy of multiple myeloma. Exp Hematol 41:508-17
Liu, Y-P; Tong, C; Dispenzieri, A et al. (2012) Polyinosinic acid decreases sequestration and improves systemic therapy of measles virus. Cancer Gene Ther 19:202-11

Showing the most recent 10 out of 13 publications